Loss of heterozygosity in the BRCA1 and BRCA2 locus in breast cancer
Автор: Tsyganov Matvey M., Ibragimova Marina K., Pevzner Alina M., Litviakov Nikolay V.
Журнал: Сибирский онкологический журнал @siboncoj
Рубрика: Лабораторные и экспериментальные исследования
Статья в выпуске: 3 т.19, 2020 года.
Бесплатный доступ
One of the factors of variability of malignant neoplasms is the loss of heterozygosity (LOH). The biological meaning of LOH, in relation to carcinogenesis, is associated with the inactivation of heterozygous loci of pathogenetically significant genes. Thus, the aim of this work was to study BRCA1/2 LOH in breast tumors. Material and Methods. The study included 122 patients with stage IIAIIIC breast cancer. DNA was isolated from 122 biopsy samples of tumor tissue using the QIAamp DNA mini Kit (Qiagen, Germany). To assess the status of LOH, microarray analysis was performed on high-density DNA chips from Affymetrix CytoScanTM HD Array. To process the results of microchipping, we used the Chromosome Analysis Suite 3.3 program (Affymetrix, USA). Results. The loss of heterozygosity in the BRCA1 gene was found to be associated with response to NAC. It was shown that in 59 patients LOH in the BRCA1gene was associated with an objective response to treatment (p=0.005). The presence of LOH in the studied genes was associated with a favorable prognosis. The 5-year non-metastatic survival rates were 75 % and 100 % in patients with LOH in the BRCA1 and BRCA2 genes, respectively (log-rank test: p=0.003 and p=0.05, respectively). Conclusion. The phenomenon of LOH in the BRCA1/2 genes was shown to be associated with response to NACT. BRCA1/2. Further studies are needed to evaluate the frequency of BRCA1/2 LOH after NAC for choosing and changing treatment tactics.
Breast cancer, brca1 and brca2 mutation in the tumor, loss of heterozygosity, microarray analysis, personalized medicine, мутация brca1 и brca2 в опухоли
Короткий адрес: https://sciup.org/140254357
IDR: 140254357 | DOI: 10.21294/1814-4861-2020-19-3-97-101
Список литературы Loss of heterozygosity in the BRCA1 and BRCA2 locus in breast cancer
- Ryland G.L., Doyle M.A., Goode D., Boyle S.E., Choong D.Y., Rowley S.M., Li J., Bowtell D.D., Tothill R.W., Campbell I.G. Loss of heterozygosity: what is it good for? BMC Med Genomics. 2015; 8: 45. doi: 10.1186/s12920-015-0123-z.
- KnudsonA.G. Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences. 1971; 68(4): 820-823.
- Chen Y., Chen C. DNA copy number variation and loss of heterozygosity in relation to recurrence of and survival from head and neck squamous cell carcinoma: a review. Head Neck. 2008; 30(10): 1361-83. doi: 10.1002/hed.20861.
- Silva J.M., Silva J., Sanchez A., Garcia J.M., Domínguez G., Provencio M., Sanfrutos L., Jareño E., Colas A., España P., Bonilla F. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clinical Cancer Research, 2002; 8(12): 3761-3766.
- Okudela K., Tateishi Y., Umeda S., Mitsui H., Suzuki T., Saito Y., Woo T., Tajiri M., Masuda M., Miyagi Y., Ohashi K. Allelic Imbalance in the miR-31 Host Gene Locus in Lung Cancer-Its Potential Role in Carcinogenesis. PLoS One. 2014 Jun 30; 9(6): e100581. doi: 10.1371/ journal.pone.0100581.
- Fleming J.L., Dworkin A.M., Allain D.C., Fernandez S., Wei L., Peters S.B., Iwenofu O.H., Ridd K., Bastían B.C., Toland A.E. Allele -specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma. Int J Cancer. 2014 Jan 1; 134(1): 244-8. doi: 10.1002/ijc.28339.
- Shikeeva A., Kekeeva T., Zavalishina L., Andreeva I., Frank G. Allelic imbalance in patients with non-small cell lung cancer. Arkh Patol. 2013; 75(2): 3-8.
- SaitoM., Okamoto A., Kohno T., TakakuraS., ShinozakiH., Isonishi S., Yasuhara T., Yoshimura T., Ohtake Y., Ochiai K., Yokota J., Tanaka T. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer. 2000; 85(2): 160-165.
- Beckmann M.W., Picard F, An H.X., van Roeyen C.R., Dominik S.I., Mosny D.S., SchnurchH.G., BenderH.G., NiederacherD. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br J Cancer. 1996 May; 73(10): 1220-6.
- MaxwellK.N., WubbenhorstB., WenzB.M., De SlooverD., Pluta J., Emery L., Barrett A., Kraya A.A., Anastopoulos I.N., Yu S., Jiang Y., ChenH., ZhangN.R., HackmanN., D'AndreaK., Daber R., Morrissette J.J.D., Mitra N., FeldmanM., Domchek S.M., Nathanson K.L. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun. 2017 Aug 22; 8(1): 319. doi: 10.1038/s41467-017-00388-9.
- Sokolenko A., Savanevich A., Stepuro T., Shulga A., Berlev I., Imyanitov E., Petrov N. Loss of heterozygosity at the BRCA1 locus as a marker of sen-sitivity for adjuvant chemotherapy in hereditary ovarian cancer. Biological Markers in Fundamental and Clinical Medicine. 2017; 1(3): 29-31.
- TelliM.L., Hellyer J., Audeh W., JensenK.C., BoseS., TimmsK.M., Gutin A., Abkevich V., Peterson R.N., Neff C., Hughes E., Sangale Z., Jones J., Hartman A.R., Chang P.J., Vinayak S., Wenstrup R., Ford J.M. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Res Treat. 2018 Apr; 168(3): 625-630. doi: 10.1007/s10549-017-4624-7.
- Pennington K.P., Walsh T., HarrellM.I., Lee M.K., Pennil C.C., Rendi M.H., Thornton A., Norquist B.M., Casadei S., Nord A.S., Agnew K.J., Pritchard C.C., Scroggins S., Garcia R.L., King M.C., Swisher E.M. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014 Feb 1; 20(3): 764-75. doi: 10.1158/1078-0432.CCR-13-2287.
- Литвяков Н.В., ЧердынцеваН.В., ЦыгановМ.М., ДенисовЕ.В., Мерзлякова М.К., Гарбуков Е.Ю., Вторушин С.В., Завьялова М.В., Слонимская Е.М. Ассоциация генетического полиморфизма с изменением экспрессии генов множественной лекарственной устойчивости в опухоли молочной железы в процессе неоадъювантной химиотрапии. Медицинская генетика. 2011; 10(10): 37-43. [Litviakov N.V., Cherdyntseva N.V., Tsyganov M.M., Denisov E.V., Merzliakova M.K., Garbukov E.Yu., Vtorushin S.V., Zavjalova M.V., Slonimskaya E.M. Influence of gene polymorphism on the expression of the multidrug resistance genes in breast tumor during neoadjuvant chemotherapy. Medical Genetics. 2011; 10(10): 37-43. (in Russian)].
- Sakr S., Abdulfatah E., Loehr A., Simmons A., Morris R., Ali-Fehmi R. Prognostic impact of loss of heterozygosity in uterine serous carcinoma. Gynecol Oncol. 2018; 149(1): 72.
